Literature DB >> 356578

Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection. A double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction.

K I Lie, K L Liem, W J Louridtz, M J Janse, A F Willebrands, D Durrer.   

Abstract

The effectiveness of intramuscular lidocaine in preventing in-hospital primary ventricular fibrillation within 1 hour after injection of the drug in patients with acute myocardial infarction was assessed in a double-blind randomized study performed in 300 such patients admitted within 6 hours of myocardial infarction. Six of 147 patients treated with 300 mg of intamuscular lidocaine had ventricular fibrillation compared with 4 of 153 control subjects. The lidocaine blood level of the patients who experienced ventricular fibrillation was 1.4 +/- 0.7 microgram/ml (mean +/- standard deviation) at the time of fibrillation, a value not significantly different from that of treated patients who did not experience fibrillation. Lidocaine blood levels in the latter were 1.9 +/- 1.1, 2.1 +/- 1.1, 2.1 +/- 1.1 and 1.7 +/- 0.7 microgram/ml, respectively, 7, 15, 30 and 60 minutes after injection. In this study intramuscular lidocaine was ineffective in preventing ventricular fibrillation, possibly because the given dose, 300 mg, prevented attainment of adequqte blood levels of the drug.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 356578     DOI: 10.1016/0002-9149(78)90945-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Potassium channel blockade: A mechanism for suppressing ventricular fibrillation.

Authors:  M B Bacaner; J R Clay; A Shrier; R M Brochu
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

2.  [Not Available].

Authors:  J Matte; J Rodrigue
Journal:  Can Fam Physician       Date:  1980-05       Impact factor: 3.275

Review 3.  Assessment of the risk-benefit ratio for antiarrhythmic drug use.

Authors:  R W Campbell
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

4.  Prophylaxis of primary ventricular fibrillation in acute myocardial infarction. The case against lignocaine.

Authors:  P Kertes; D Hunt
Journal:  Br Heart J       Date:  1984-09

5.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

6.  Prehospital and hospital coronary care.

Authors:  P C Baumann
Journal:  Intensive Care Med       Date:  1978-01       Impact factor: 17.440

Review 7.  Comparison of drug dosing methods.

Authors:  M E Burton; M R Vasko; D C Brater
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

8.  Prophylaxis of primary ventricular fibrillation with tocainide in acute myocardial infarction.

Authors:  R W Campbell; I Hutton; R A Elton; R M Goodfellow; E Taylor
Journal:  Br Heart J       Date:  1983-06

Review 9.  Reliability of antiarrhythmic drug plasma concentration monitoring.

Authors:  F Follath; U Ganzinger; E Schuetz
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

10.  The effects of lidocaine on the ventricular fibrillation threshold and primary ventricular fibrillation following acute experimental coronary occlusion.

Authors:  B Krämer; H Gülker; W Meesmann
Journal:  Basic Res Cardiol       Date:  1981 Jan-Feb       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.